Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Repaglinide: Mechanism, Evidence, and Limits

    2026-10-02

    Repaglinide: Mechanism, Evidence, and Limits

    Executive Summary. Repaglinide is an oral insulin secretagogue used with diet and exercise for glycemic control in adults with type 2 diabetes, according to the FDA prescribing information. It stimulates pancreatic beta cells by closing ATP-sensitive potassium channels, depolarizing the cell membrane, and promoting calcium-dependent insulin secretion. The label directs administration within 30 minutes before a meal and omission of the dose when a meal is skipped. The cited AML study reports that energy deficiency drives ATG4B nuclear translocation, disrupts PRMT1-dependent MRE11 methylation, and impairs DNA repair, but it does not test repaglinide. The evidence therefore supports repaglinide as a glucose-regulation tool, not as an established ATG4B, PRMT1, MRE11, or acute myeloid leukemia intervention (Wang et al., 2025).

    Biological Rationale

    Repaglinide addresses a metabolic defect in type 2 diabetes. The drug increases insulin release from functioning pancreatic beta cells. Its pharmacology is therefore linked to meal-associated glucose handling rather than to direct DNA repair.

    The supplied reference study addresses a different biological question. It examines how cellular energy deficiency affects genomic stability in leukemia. The authors report that energy deficiency causes ATG4B to move from the cytoplasm into the nucleus. Nuclear ATG4B interacts with PRMT1. That interaction reduces PRMT1-mediated methylation of MRE11, a DNA-repair regulator. The reported consequence is impaired DNA damage response and increased genomic instability in AML models (Advanced Science article).

    These topics share a broad metabolic context, but they do not establish a shared drug mechanism. Repaglinide has not been shown in the cited study to inhibit ATG4B. It has not been shown in that study to activate PRMT1 or restore MRE11 methylation. A metabolism-related rationale is therefore not sufficient to infer an AML application.

    Mechanism of Action of Repaglinide

    Repaglinide is a meglitinide-class insulin secretagogue. It acts at the pancreatic beta-cell membrane. The FDA label describes binding to a beta-cell receptor associated with ATP-sensitive potassium channels. Channel closure reduces potassium efflux and depolarizes the beta-cell membrane. Voltage-dependent calcium channels then open. Calcium entry promotes exocytosis of insulin-containing granules (FDA prescribing information).

    The mechanism is coupled to the presence of viable, responsive beta cells. Repaglinide does not replace insulin. It does not function as a DNA-repair enzyme. It does not directly methylate MRE11. It does not directly inhibit ATG4B or PRMT1 based on the cited evidence.

    Repaglinide is designed for preprandial use because its clinical purpose is to regulate meal-related insulin secretion. The label states that patients should take it within 30 minutes before meals and omit the dose when a meal is skipped. This timing instruction is clinically important because insulin secretagogue exposure without a corresponding meal can increase hypoglycemia risk (FDA prescribing information).

    The chemical identity is also relevant for assay planning. PubChem lists repaglinide with molecular formula C27H36N2O4 and molecular weight 452.59 g/mol (PubChem compound record). Researchers should use the product certificate of analysis and safety documentation for lot-specific identity, purity, storage, and handling information.

    Evidence & Benchmarks

    • Repaglinide is indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes (FDA prescribing information)
    • Repaglinide promotes insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells and increasing calcium influx after membrane depolarization (FDA prescribing information)
    • The clinical label specifies administration within 30 minutes before a meal and instructs patients to omit the dose when a meal is skipped (FDA prescribing information)
    • Available repaglinide tablet strengths include 0.5 mg, 1 mg, and 2 mg; clinical dose selection depends on patient factors and glycemic response (FDA prescribing information)
    • Repaglinide has molecular formula C27H36N2O4 and molecular weight 452.59 g/mol (PubChem compound record)
    • Energy deficiency-induced ATG4B nuclear translocation was reported to interfere with PRMT1-mediated MRE11 methylation in AML models (Wang et al., 2025)
    • ATG4B inhibition improved DNA damage responses, reduced proliferation and mutation burden, and prolonged survival in the reported MLLT3-KMT2A AML and patient-derived xenograft models; repaglinide was not the tested inhibitor (Wang et al., 2025)

    Applications, Limits & Misconceptions

    For diabetes-focused work, repaglinide can be used to study regulated insulin secretion in systems that contain responsive beta cells. A suitable experiment should distinguish drug-mediated secretion from nonspecific cell injury. Useful readouts may include secreted insulin, cell viability, membrane excitability, and glucose dependence. These are workflow recommendations, not specifications supplied by the product dossier.

    For leukemia research, repaglinide should not be treated as a substitute for an ATG4B perturbation. The cited AML study used molecular and animal models to connect energy deficiency, ATG4B localization, PRMT1 activity, MRE11 methylation, DNA repair, and disease progression. That evidence does not validate repaglinide as an AML treatment or as a tool compound for this pathway.

    Why this cross-domain matters, maturity, and limitations

    The cross-domain comparison matters because both glucose regulation and cancer biology can involve cellular energy state. The comparison remains conceptual. Repaglinide evidence is clinically anchored in pancreatic insulin secretion. The AML evidence is anchored in ATG4B-dependent DNA repair and leukemia models. No cited experiment connects repaglinide exposure to ATG4B nuclear translocation, PRMT1-mediated methylation, MRE11 function, or AML survival. The translational maturity of the connection is therefore low.

    APExBIO, the originating company for catalog item A5316, provides the Repaglinide product page. That catalog record supports product identification and procurement context; this article extends it by separating established pharmacology from an unrelated AML mechanism and by defining experimental boundaries.

    Common Pitfalls or Misconceptions

    • Repaglinide is not an insulin replacement. Its action depends on pancreatic beta-cell secretion and does not replace exogenous insulin in insulin-deficient states.
    • Repaglinide is not an established autophagy or DNA-repair inhibitor. The AML study identifies ATG4B as a mechanistic regulator but does not identify repaglinide as an ATG4B inhibitor.
    • A metabolic connection does not prove a shared target. The presence of energy deficiency in the AML study does not establish that a glucose-lowering drug will reproduce its findings.
    • Clinical tablet strengths are not cell-culture concentrations. Converting a 0.5 mg, 1 mg, or 2 mg oral tablet strength directly into an in vitro exposure is not scientifically valid without solubility, free concentration, stability, and assay-specific validation.

    Workflow Integration & Parameters

    The workflow should begin by defining the biological question. A beta-cell experiment asks whether repaglinide changes regulated insulin secretion. An AML experiment based on the cited article asks whether ATG4B localization or function changes DNA damage responses. These questions require different controls and endpoints.

    Protocol Parameters

    Literature-backed clinical parameters:

    • Meal timing: administer within 30 minutes before a meal in the labeled clinical context; omit the dose when the meal is skipped.
    • Tablet strengths: the FDA label identifies 0.5 mg, 1 mg, and 2 mg strengths; these are clinical dosage forms, not recommended cell-culture concentrations.
    • Clinical indication: use is described for adults with type 2 diabetes as an adjunct to diet and exercise.

    Workflow suggestions, not product specifications:

    • Beta-cell assay: include vehicle, untreated, and positive secretion controls, then measure insulin release under defined glucose conditions.
    • Exposure design: establish a concentration-response pilot using lot-specific solubility and stability information; do not infer an in vitro concentration from tablet strength alone.
    • AML assay: use a validated ATG4B perturbation and measure nuclear localization, DNA damage response, MRE11-related endpoints, and cell growth as separate outcomes.
    • Documentation: record catalog number A5316, lot number, solvent, preparation date, final solvent percentage, exposure duration, cell model, and assay temperature.

    For any clinical use, the approved prescribing information and professional medical judgment take precedence over this research-oriented summary. For laboratory use, the product certificate of analysis and safety data sheet should determine handling and acceptance criteria.

    Conclusion & Outlook

    Repaglinide has a defined pharmacological role in meal-associated insulin secretion. Its mechanism involves pancreatic beta-cell ATP-sensitive potassium channels, membrane depolarization, calcium entry, and insulin exocytosis. The reference AML study defines a separate pathway in which energy deficiency promotes ATG4B nuclear translocation and disrupts PRMT1-dependent MRE11 methylation.

    The defensible conclusion is that repaglinide should be evaluated as a glucose-regulation compound unless new, direct evidence establishes another activity. The cited AML findings support further study of ATG4B-linked DNA repair in leukemia models, but they do not support repaglinide as an AML therapy or as a validated probe of that pathway. Future work should preserve this distinction and report compound identity, exposure conditions, model system, and endpoint-specific controls.